This is a non-interventional, observational, cross-sectional study of prescribers of Instanyl®.~This study will assess the prescribers' awareness of the updated EMs and changes in prescribers' knowledge and understanding of the key information contained in the updated EMs. The study will enroll approximately 768 prescribers. The first survey (pre-EM survey) will be conducted three months before the distribution of updated EMs, second survey (post-EM survey) will be conducted six months following the distribution of updated EMs.~The data will be collected, through a self-administered web-based questionnaire. All participants will be enrolled in a single observational group:~• Prescriber of Instanyl®~This multi-center study will be conducted in France, Germany, Netherlands, Poland and Spain. The overall duration of the study will be approximately 22 months.
The purpose of the Instanyl study is to learn how much doctors know and understand about Instanyl® before and after they receive updated educational information, including the risks of its unapproved use. In this study, the doctors will complete two surveys: one three months before they receive the updated educational information, and one about six months after they receive this information. They will answer questions about their prescribing behavior plus their knowledge of Instanyl® including any risks.